Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187063 · ClinicalTrials.gov registry record · NA
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
A NA study of Non-muscle Invasive Bladder Cancer (NMIBC), sponsored by Lahey Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT07187063: Recruiting NA study of Non-muscle Invasive Bladder Cancer (NMIBC), sponsored by Lahey Clinic.
NCT07187063 is a NA study of Non-muscle Invasive Bladder Cancer (NMIBC) that is actively recruiting participants, run by Lahey Clinic. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07187063, a NA study of Non-muscle Invasive Bladder Cancer (NMIBC), is actively recruiting participants, sponsored by Lahey Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Primary Outcome
The rate of cystoscopies (cystoscopies per month), compared between the De-intensified and the standard surveillance arms, is the primary outcome measure.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST UroAmp Test (Convergent Genomics, Inc.)
Study Locations (1)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
What NCT07187063 shows while recruiting
NCT07187063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer (NMIBC) appearing as the primary indexed condition, and to 1 intervention - of which UroAmp Test (Convergent Genomics, Inc.) is the first listed.
NCT07187063 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07187063 about?
NCT07187063 is a clinical study titled "Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer". The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
What is the current status of trial NCT07187063?
This trial is currently recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2025-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT07187063 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer (NMIBC).
What interventions are being tested in trial NCT07187063?
The interventions under investigation include: UroAmp Test (Convergent Genomics, Inc.) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07187063?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07187063 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer (NMIBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07187063's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI